Cargando…

SFRP1 is a possible candidate for epigenetic therapy in non-small cell lung cancer

BACKGROUND: Non-small cell lung cancer (NSCLC) remains a lethal disease despite many proposed treatments. Recent studies have indicated that epigenetic therapy, which targets epigenetic effects, might be a new therapeutic methodology for NSCLC. However, it is not clear which objects (e.g., genes) th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taguchi, Y-h., Iwadate, Mitsuo, Umeyama, Hideaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989892/ https://www.ncbi.nlm.nih.gov/pubmed/27534621 http://dx.doi.org/10.1186/s12920-016-0196-3

Ejemplares similares

TINAGL1 and B3GALNT1 are potential therapy target genes to suppress metastasis in non-small cell lung cancer
por: Umeyama, Hideaki, et al.
Publicado: (2014)

Genes associated with genotype-specific DNA methylation in squamous cell carcinoma as candidate drug targets
por: Kinoshita, Ryoichi, et al.
Publicado: (2014)

Principal component analysis-based unsupervised feature extraction applied to in silico drug discovery for posttraumatic stress disorder-mediated heart disease
por: Taguchi, Y-h, et al.
Publicado: (2015)

Bioinformatic Screening of Autoimmune Disease Genes and Protein Structure Prediction with FAMS for Drug Discovery
por: Ishida, Shigeharu, et al.
Publicado: (2014)

Epigenetics of SFRP1: The Dual Roles in Human Cancers
por: Baharudin, Rashidah, et al.
Publicado: (2020)

Development of a novel anti-hepatitis B virus agent via Sp1
por: Hayakawa, Michiyo, et al.
Publicado: (2020)

Author Correction: Development of a novel anti-hepatitis B virus agent via Sp1
por: Hayakawa, Michiyo, et al.
Publicado: (2020)

DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer
por: Zhu, Jian, et al.
Publicado: (2012)

Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer
por: Cheng, Y Y, et al.
Publicado: (2007)

LUCAT1 Epigenetically Downregulates the Tumor Suppressor Genes CXXC4 and SFRP2 in Gastric Cancer
por: Byun, Hyo Joo, et al.
Publicado: (2020)

DNA methylation of SFRP1, SFRP2, and WIF1 and prognosis of postoperative colorectal cancer patients
por: Liu, Xinyan, et al.
Publicado: (2019)

SFRP Tumour Suppressor Genes Are Potential Plasma-Based Epigenetic Biomarkers for Malignant Pleural Mesothelioma
por: Cheng, Yuen Yee, et al.
Publicado: (2017)

Study of SFRP1 and SFRP2 methylation status in patients with de novo Acute Myeloblastic Leukemia
por: Ghasemi, Ali, et al.
Publicado: (2015)

Wnt pathway antagonists, SFRP1, SFRP2, SOX17, and PPP2R2B, are methylated in gliomas and SFRP1 methylation predicts shorter survival
por: Majchrzak-Celińska, Aleksandra, et al.
Publicado: (2015)

Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies
por: Carter, Corey A., et al.
Publicado: (2016)

Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer
por: Veeck, Jürgen, et al.
Publicado: (2008)

Diabetic Osteopenia by Decreased β-Catenin Signaling Is Partly Induced by Epigenetic Derepression of sFRP-4 Gene
por: Mori, Kiyoshi, et al.
Publicado: (2014)

Epigenetic Regulation of Glucose Transporters in Non-Small Cell Lung Cancer
por: O'Byrne, Kenneth J., et al.
Publicado: (2011)

Epigenetic upregulation of HOXC10 in non-small lung cancer cells
por: Li, Miao, et al.
Publicado: (2020)

The role of dexamethasone in mediating the contradictory effects of Wnt antagonists SFRP2 and SFRP3 on human hair follicle growth
por: Hamida, Ons Ben, et al.
Publicado: (2023)

SFRP4 gene expression is increased in aggressive prostate cancer
por: Sandsmark, Elise, et al.
Publicado: (2017)

Epigenetic Therapy of Non-Small Cell Lung Cancer Using Decitabine (5-Aza-2′-Deoxycytidine)
por: Momparler, Richard L.
Publicado: (2013)

A Screening of Epigenetic Therapeutic Targets for Non-Small Cell Lung Cancer Reveals PADI4 and KDM6B as Promising Candidates
por: Lesbon, Jéssika Cristina Chagas, et al.
Publicado: (2022)

Identification of Withaferin A as a Potential Candidate for Anti-Cancer Therapy in Non-Small Cell Lung Cancer
por: Hsu, Jade H.-M., et al.
Publicado: (2019)

Cross-talk with lung epithelial cells regulates Sfrp2-mediated latency in breast cancer dissemination
por: Montagner, Marco, et al.
Publicado: (2020)

The role of Sfrp and DKK proteins in cardiomyocyte development
por: Hsueh, Ying‐Chang, et al.
Publicado: (2021)

sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance
por: Kaur, Amanpreet, et al.
Publicado: (2016)

EZH2 regulates sFRP4 expression without affecting the methylation of sFRP4 promoter DNA in colorectal cancer cell lines
por: Liu, Yuting, et al.
Publicado: (2020)

Epigenetic Therapy in Lung Cancer
por: Liu, Stephen V., et al.
Publicado: (2013)

LINC01089 Inhibits Tumorigenesis and Epithelial–Mesenchymal Transition of Non-small Cell Lung Cancer via the miR-27a/SFRP1/Wnt/β-catenin Axis
por: Li, Xingkai, et al.
Publicado: (2020)

Identification and validation of candidate epigenetic biomarkers in lung adenocarcinoma
por: Daugaard, Iben, et al.
Publicado: (2016)

Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer
por: Berardi, Rossana, et al.
Publicado: (2013)

Epigenetic therapy potential of suberoylanilide hydroxamic acid on invasive human non-small cell lung cancer cells
por: Zhang, Shirong, et al.
Publicado: (2016)

Epigenetic reprogramming in small cell lung cancer
por: Chen, Jingyao, et al.
Publicado: (2022)

In silico Identification of SFRP1 as a Hypermethylated Gene in Colorectal Cancers
por: Kim, Jongbum, et al.
Publicado: (2014)

Feasibility of Plasma-Methylated SFRP2 for Early Detection of Gastric Cancer
por: Miao, Jin, et al.
Publicado: (2020)

SFRP4 drives invasion in gastric cancer and is an early predictor of recurrence
por: Busuttil, Rita A., et al.
Publicado: (2020)

SFRP4 Is a Potential Biomarker for the Prognosis and Immunotherapy for Gastric Cancer
por: Yu, Pengcheng, et al.
Publicado: (2022)

Aberrant expression of SFRP1, SFRP3, DVL2 and DVL3 Wnt signaling pathway components in diffuse gastric carcinoma
por: Sremac, Maja, et al.
Publicado: (2021)

SFRP2 Is Associated with Increased Adiposity and VEGF Expression
por: Crowley, Rachel K., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_o998ndharif4ar867v19vgjdpb